FDAFDA PCAC reviews BPC-157, KPV, TB-500, MOTS-c (Jul 23) and DSIP, Semax, Epitalon (Jul 24, 2026) for 503A compounding eligibilityUPDATESemaglutide and tirzepatide compounding ended — shortage resolved Feb/May 2025REGULATORY12 peptides removed from FDA Category 2 (Apr 23, 2026) — removal is not approval; all remain pending PCAC reviewREGULATORYNo formal FDA reclassification published — no restricted peptide is legal to compound; 5 more peptides go to PCAC before Feb 2027RESEARCHA Real-world Study of Treatment Retention and Adherence to Secukinumab in Patients With Plaque Psoriasis (PsO) With or Without Glucagon-like Peptide-1 Receptor Agonist (GLP-1 RA) Co-therapy [NCT07881783]RESEARCHStudy to Evaluate the Dose-Dependent Effect of Tirzepatide on Gastric Emptying in Adult Patients With Type 1 Diabetes [NCT07951658]RESEARCHA Study of Investigational Tirzepatide (LY3298176) Doses in Participants With Type 2 Diabetes and Obesity [NCT06037252]RESEARCHA Study to Learn About the Study Medicine Called Rimegepant in Adults When Used for the Prevention of Chronic Migraine [NCT07729462]RESEARCHHypersensitivity to Amylin in Post-Traumatic Headache [NCT07340775]RESEARCHEffects of Tirzepatide on Corneal Nerve Morphology and Other Ocular Parameters in Adults With Obesity [NCT07950371]NEWSSTAT+: Peptide market poised to explode with new Hims and Noom launchesRESEARCHAlleviating Carbohydrate Counting for Patients With Type-1 Diabetes Using a Closed Loop System With Weekly Subcutaneous Semaglutide [NCT06387199]RESEARCHWeight Trajectories and Predictive Factors After Semaglutide in Patients With Grade 3 and Complicated Obesity [NCT07423481]RESEARCHSEMAFORCRANIO : Multicenter, Double-blind, Parallel, Randomized Controlled Trial of the Efficacy of Semaglutide in Hypothalamic Obesity Secondary to Craniopharyngioma in Children Aged 12 to 17 Years [NCT07845994]FDAFDA PCAC reviews BPC-157, KPV, TB-500, MOTS-c (Jul 23) and DSIP, Semax, Epitalon (Jul 24, 2026) for 503A compounding eligibilityUPDATESemaglutide and tirzepatide compounding ended — shortage resolved Feb/May 2025REGULATORY12 peptides removed from FDA Category 2 (Apr 23, 2026) — removal is not approval; all remain pending PCAC reviewREGULATORYNo formal FDA reclassification published — no restricted peptide is legal to compound; 5 more peptides go to PCAC before Feb 2027RESEARCHA Real-world Study of Treatment Retention and Adherence to Secukinumab in Patients With Plaque Psoriasis (PsO) With or Without Glucagon-like Peptide-1 Receptor Agonist (GLP-1 RA) Co-therapy [NCT07881783]RESEARCHStudy to Evaluate the Dose-Dependent Effect of Tirzepatide on Gastric Emptying in Adult Patients With Type 1 Diabetes [NCT07951658]RESEARCHA Study of Investigational Tirzepatide (LY3298176) Doses in Participants With Type 2 Diabetes and Obesity [NCT06037252]RESEARCHA Study to Learn About the Study Medicine Called Rimegepant in Adults When Used for the Prevention of Chronic Migraine [NCT07729462]RESEARCHHypersensitivity to Amylin in Post-Traumatic Headache [NCT07340775]RESEARCHEffects of Tirzepatide on Corneal Nerve Morphology and Other Ocular Parameters in Adults With Obesity [NCT07950371]NEWSSTAT+: Peptide market poised to explode with new Hims and Noom launchesRESEARCHAlleviating Carbohydrate Counting for Patients With Type-1 Diabetes Using a Closed Loop System With Weekly Subcutaneous Semaglutide [NCT06387199]RESEARCHWeight Trajectories and Predictive Factors After Semaglutide in Patients With Grade 3 and Complicated Obesity [NCT07423481]RESEARCHSEMAFORCRANIO : Multicenter, Double-blind, Parallel, Randomized Controlled Trial of the Efficacy of Semaglutide in Hypothalamic Obesity Secondary to Craniopharyngioma in Children Aged 12 to 17 Years [NCT07845994]

研究用のみ。 完全な免責事項 →

研究/Peptide Therapy Shows Promise During Ramadan for Type 2 Diabetes
研究ライブラリに戻る

Peptide Therapy Shows Promise During Ramadan for Type 2 Diabetes

May 25, 2026
Share
発展中の研究

これらは有望ですが、さらなる検証が必要な発展途上の見解に基づいています。

この分析について

この記事は、最近のニュースアイテムや臨床試験リストのAI補助要約です。ペプチド研究コミュニティにとって迅速でアクセスしやすい概要を提供することを目的としています。正確性のために常に下記リンク先の元のソースをご確認ください。

Peptide Therapy Shows Promise During Ramadan for Type 2 Diabetes

A groundbreaking study conducted by Eli Lilly and Company has concluded that a novel peptide therapy, tirzepatide (LY3298176), can effectively manage type 2 diabetes in patients who observe the month-long Islamic fast of Ramadan. This research offers hope to millions around the world who struggle with balancing their health needs during religious observances.

Background

Ramadan is a holy month for Muslims, during which fasting occurs from dawn until sunset. For individuals managing chronic conditions like type 2 diabetes, this period presents unique challenges as it can disrupt routine medication schedules and dietary habits. Traditionally, patients have had to adjust their insulin and other treatments, often leading to fluctuations in blood glucose levels. The introduction of tirzepatide offers a new avenue for maintaining stable blood sugar levels without the need for significant adjustments.

Tirzepatide is a dual GIP and GLP-1 receptor agonist that has already shown efficacy in managing type 2 diabetes by improving glycemic control, reducing body weight, and lowering cardiovascular risk factors. The study's completion marks an important milestone in understanding how this peptide therapy can be utilized during periods of fasting.

Key Details

The completed clinical trial, NCT06635057, was designed to assess the safety and efficacy of initiating tirzepatide before Ramadan and continuing it throughout the month. The study included participants with type 2 diabetes who were eligible for Ramadan fasting based on their medical condition.

Researchers found that participants who used tirzepatide maintained stable blood glucose levels without the need for significant dietary adjustments or additional medications commonly required during fasting periods. This outcome is a critical step in confirming the viability of peptide therapies as effective management tools during religious observances and other situations where traditional treatment approaches may be less practical.

Key Takeaways

  • Effective Management: Tirzepatide can help maintain stable blood glucose levels for individuals with type 2 diabetes who fast.
  • No Dietary Adjustments Needed: Patients using tirzepatide did not require major changes to their diet during Ramadan, simplifying management of the condition.
  • Safety and Efficacy: The study confirmed that initiating treatment before fasting periods and continuing it throughout provides a consistent level of control over blood sugar levels.
  • Clinical Validation: This research adds significant clinical data to the growing body of evidence supporting peptide therapy in managing type 2 diabetes.

What This Means

The results of this study highlight the potential for peptide therapies like tirzepatide to offer flexible and effective solutions for patients with chronic conditions who face unique challenges during religious observances or other fasting periods. As more research continues, these findings could pave the way for broader applications of peptide-based treatments in managing type 2 diabetes and potentially other metabolic disorders.

For the peptide community, this study underscores the importance of ongoing clinical trials and regulatory oversight to ensure that innovative therapies like tirzepatide can be safely and effectively integrated into patient care plans. It also emphasizes the need for continued research into how such treatments perform under various conditions and lifestyles.

---

Source: ClinicalTrials.gov — Published 2026-05-22

This article is for informational purposes only and does not constitute medical advice.

編集者の注

この分析はAIツールを使用して生成され、Peptide Contacts編集部がレビューしました。正確性を追求していますが、AI生成のコンテンツには誤りや省略がある可能性があります。情報確認のために常に元のソースをご確認ください。 元のソース 詳細、方法論、データについては

Peptide Contactsは、情報提供のために-curated研究要約を提供しています。このコンテンツは医療アドバイスにはなりません。健康決定をする前に常に格付けされた医療専門家に相談してください。

Comments

Sign in to join the discussion

この記事はAIを使用して生成され、誤りや省略がある可能性があります。情報提供のために提供されていますが、医療アドバイスにはなりません。常に元のソースを確認し、格付けされた医療専門家に相談してください。